Epcoritamab Misses the U.S. Phase 3 Endpoint
Genmab and AbbVie clarified on July 23 that overall survival — the sole U.S. primary endpoint in Phase 3 EPCORE DLBCL-1 — was not met. The randomized trial had previously shown a progression-free-survival hazard…
